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Abstract Enhancing the potency of peptides is a critical and 
important step in the development of peptide drugs. We have 
proposed that proline residues flanking protein-protein interac- 
tion sites perform a structural role in enhancing their interaction 
[R.M. Kini and H.J. Evans, Biochem. Biophys. Res. Commun. 
212 (1995) 1115-1124]. To test this theory, we incorporated pro- 
line residues on either or both sides of the interaction site of an 
antiplatelet peptide, IARGDMNA and determined the inhibitory 
potency of the peptides in whole blood aggregation. Inclusion of 
one proline residue, on either the amino or carboxy terminal side 
of the interaction site, enhances the antiplatelet activity to ap- 
proximately the same extent (1.5- to 2.5-fold). Incorporation of 
proline residues on both sides enhances the activity by 7- to 13- 
fold. This enhancement of the biological activity of the peptide 
is probably due to a reduction in the number of possible conforma- 
tions of the peptide, without introducing the rigidity that would 
accompany cyclization. Incorporation of proline brackets thus 
provides a novel approach to the design and development of more 
potent peptide drugs and ligands. 
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I. Introduction 
Several bioactive peptide drugs interfere in protein-protein 
interactions. The potency of bioactive peptides is directly pro- 
portional to their ability to interact with their target proteins. 
Structural features that enhance the protein-protein i terac- 
tions can therefore contribute to the design and development 
of potent bioactive peptides. Recently, by a survey of over 1600 
protein protein interaction sites, we recognized that proline is 
the most common amino acid residue found in the flanking 
segments of interaction sites [1]. We proposed that proline 
residues prevent the extension of neighboring secondary struc- 
tures and thus protect he conformation and integrity of inter- 
action sites. These proline residues also help in the presentation 
of interaction sites [1]. If this hypothetical structural role is true, 
it is logical to propose that the incorporation fproline residues 
around a bioactive peptide might enhance its potency signifi- 
cantly. In this report, we therefore xamined the effect of incor- 
poration of proline residues on the antiplatelet potency of pep- 
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tides containing the Arg-Gly-Asp (RGD) sequence. We chose 
to study the effect of incorporation of proline brackets in an 
antiplatelet peptide for the following reasons: (a) development 
of antiplatelet drugs is important in the prevention/treatment 
of atherosclerosis, myocardial infarction, stroke and cancer 
[24]; (b) the proteins involved in platelet aggregation a d other 
adhesive interactions are structurally and immunologically re- 
lated [5]; and (c) platelet aggregation, a specialized adhesive 
reaction, is easy to monitor by facile methods. Platelet aggrega- 
tion is mediated via interaction between platelet integrin, the 
glycoprotein l ib- I l ia  complex, and adhesive protein ligands, 
such as fibrinogen, fibronectin and von Willebrand factor [6,7] 
The Arg-Gly-Asp (RGD) tripeptide is the most common 
molecular recognition site implicated in several of these interac- 
tions [8-10]. Small peptides containing the RGD sequence in- 
hibit adhesive reactions including platelet aggregation. We se- 
lected IARGDMNA as a typical RGD-containing peptide, 
since related sequences are found in disintegrins, the most po- 
tent inhibitors of platelet aggregation, from snake venoms [11- 
13]. Proline residues were substituted on either side or both 
sides of the RGDM sequence. All four peptides, IARGDMNA, 
IARGDMPA, IPRGDMNA and IPRGDMPA, were synthe- 
sized by solid phase peptides ynthesis. The effect of incorpora- 
tion of proline residues on the antiplatelet ffect was studied. 
2. Materials and methods 
2.1. Materials 
t-Butyloxycarbonyl (t-BOC) amino acids and trifluoroacetic acid 
were obtained from Advanced Chemtech, and other eagents and sol- 
vents were obtained from Fisher Scientific. Collagen and ADP used to 
initiate platelet aggregation were from Chrono-Log Corp. 
2.2. Peptide synthesis 
We synthesized peptides using t-BOC chemistry on Merrifield resin 
[14], using a Milligen/Biosearch Model 9600 peptide synthesizer. After 
extraction, the peptides were purified by reverse phase HPLC to more 
than 95% purity, with yields between 80 and 90%. Amino acid analyses 
were performed after 24 h hydrolysis of the peptides in 6 N HC1 at 
110°C. The amino acid compositions were similar to those xpected 
from the sequences of the peptides within experimental errors. The 
structures were also confirmed by determining the mass by fast atom 
bombardment mass pectra on a Finnegan TSQ 70 mass pectrometer. 
The masses of IARGDMNA, IPRGDMNA, IARGDMPA and 
IPRGDMPA as determined by mass pectrometry were 847 (846.96 
calculated), 873 (873.00), 831 (829.97) and 855 (856.01), respectively. 
2.3. Platelet aggregations 
Blood was drawn and anticoagulated with 0.11 M trisodium citrate 
(1 : 9, v/v), from healthy volunteers who had not taken any medications 
or alcohol in the previous week. The citrated blood was diluted 1 : 1 with 
phosphate-buffered saline, and 1 ml of the diluted blood was incubated 
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with various amounts of peptide or buffer at 37°C for 2 min. Platelet 
aggregation was initiated by the addition of 2/ll collagen (1 mg/ml) or 
ADP (10/IM final concentration). The aggregation was measured as 
the increase inelectrical impedance in a whole blood aggregometer [15]. 
The percent inhibition was calculated by comparing the impedance of
the aggregation curves 5 min after the addition of collagen or ADP, 
taking the impedance ofthe control curves as 100% aggregation. 
3. Results and discussion 
We examined the effect of the peptides, IARGDMNA, 
IPRGDMNA, IARGDMPA and IPRGDMPA, on whole 
blood aggregation. This assay system more closely mimics 
physiological conditions than the aggregation of washed or 
gel-filtered platelets. Moreover, there is a direct correlation 
between i hibition of binding of fibrinogen to glycoprotein I Ib- 
IIIa complex and platelet aggregation [16]. All four peptides 
inhibited platelet aggregation (Fig. 1). To compare inhibitory 
potencies, we determined the dose-response r lationships for 
all the peptides (Fig. 2). We estimated IC5o values (concentra- 
tion of the peptide that inhibits platelet aggregation by 50%) 
from the dose-response curves and the fold increase in the 
inhibitory potencies (Table 1). As expected according to our 
proposal, the inhibitory potencies of the peptides were 
IPRGDMPA > IPRGDMNA = IARGDMPA > IARGDMNA. 
The potency of IARGDMNA is comparable with that of the 
RGDS peptide [17]. Incorporation ofa proline residue on either 
side of RGDM enhances the potency to about he same extent. 
Inclusion of proline residues on both sides enhanced the anti- 
platelet effect of the RGD peptide by 7- to 13-fold. These results 
show that proline brackets enhance the biological activity of the 
antiplatelet peptide by amplifying its ability to interfere in the 
interaction between fibrinogen and its receptor [16]. 
In proteins proline brackets protect and present protein- 
protein interaction sites [1]. In small peptides containing the 
minimum molecular recognition sites, since there are no adja- 
cent secondary structures, proline brackets probably help in the 
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Fig. 1. Effect of various peptides on platelet aggregation. Panel A: 
ADP-induced aggregation. Curves 2, 3 and 4 show the effect of 15/xM 
IARGDMNA, 12.5/2M IARGDMPA and 3.5/tM IPRGDMPA, re- 
spectively, on control aggregation (curve 1). Panel B: collagen-induced 
aggregation. Curves 2, 3 and 4 show the effect of 50/2M IARGDMNA, 
20/2M IARGDMPA and 10,uM IPRGDMPA, respectively, oncontrol 
aggregation (curve 1). The arrow indicates the addition of either ADP 
(10 HM) or collagen (2/2g) to initiate aggregation. The increase in the 
impedance of the aggregation i duced by collagen is larger than that 
induced by ADP [20]. Typical of at least wo experiments. Similar 
relative inhibitory potencies for the peptides were observed in several 
independent experiments performed on separate days. 
A 
t- 
O 
i i  
m 
o') 
< 
100  
50  
0 
100  
50  
10 100 
X o 
• 0 0 V 
10 100  
[PepUde] (pM) 
Fig. 2. Dose response curves of various peptides on platelet aggrega- 
tion. Various amounts of individual peptides were incubated with di- 
luted whole blood for two min at 37°C before the addition of ADP 
(panel A) or collagen (panel B). e, IPRGDMPA; o, IARGDMNA; A, 
IARGDMPA; and V, IPRGDMNA. Dose-response curves hown here 
are obtained from the blood of donor 1. Similar curves were also 
obtained using the blood of donor 2. Similar elative potencies were 
observed when experiments were performed on at least hree separate 
days. The collagen-induced aggregation is comparatively more resistant 
to inhibition. 
presentation f the site. In these peptides, the lack of secondary 
structure-stabilizing features, such as reinforcing hydrogen 
bonds, prevent definite secondary structures, and the peptides 
occur in many relatively unstable conformations. Since proline 
limits the flexibility around the s-carbon atoms [1], the number 
of possible conformations would be drastically reduced. Thus, 
the peptide with the proper conformation would be much more 
probable, resulting in greater potency of peptides with proline 
brackets. Further studies are required to clarify the contribu- 
tion of proline brackets to the secondary structures of these 
peptides under various experimental conditions. 
The potency of peptides can also be enhanced by cyclization 
[18,19] which also reduces the number of conformations. Un- 
like the case with proline brackets, the conformational re- 
straints in cyclization are due to a covalent cross-link, which 
may reduce the flexibility too much and even result in strain at 
the interaction site and loss of its function. Proline brackets, 
however, introduce no undue strain along the backbone, and 
thus allow the flexibility of the interaction site. An increase in 
potency of 10- to 15-fold is highly significant and can be critical 
in development of bioactive peptides. For example, Barker et 
al. synthesized more than 80 cyclic RGD peptide analogs and 
obtained a potent platelet aggregation i hibitor, G-4120, with 
an IC5o of 0.15/.tM [18]. The peptide with complete proline 
brackets, IPRGDMPA, inhibits platelet aggregation with an 
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Table 1 
Effect of proline brackets on potency of inhibition of platelet aggrega- 
tion 
Peptide Donor 1 Fold Donor 2 Fold 
(female) (male) 
IC5o ~uM) IC5o (tiM) 
Collagen-induced aggregation 
IARGDMNA 84.5 - 67.3 
IPRGDMNA 48.8 1.73 27.6 2.44 
IARGDMPA 37.5 2.25 27.6 2.44 
IPRGDMPA 6.4 13.10 8.4 8.01 
RGDS 57.8 32.3 
ADP-induced aggregation 
IARGDMNA 27.3 22.5 - 
IPRGDMNA 21.5 1.27 18.9 1.19 
IARGDMPA 21.0 1.30 16.7 1.34 
IPRGDMPA 4.03 6.77 2.2 10.27 
RGDS 29.9 13.75 - 
IC5o values were calculated from two separate individuals. Similar 
dose-responses and inhibitory potencies were obtained by repeating 
these studies. The values are within 20% confidence limits. 
*The inhibitory potency of each peptide was compared with that of 
IARGDMNA to obtain the fold increase in its potency. 
IC5o of 2 .24.0 ~M. Simply by including proline brackets, we 
obtained a potent antiplatelet peptide that should provide a 
strong starting point for the development of more potent an- 
tithrombotic peptides. Thus this novel approach of incorpora- 
tion of proline brackets provides a viable alternative to cycliza- 
tion in the design and development of potent peptide drugs and 
ligands, a critical step in their development as drugs. These 
results provide strong support for our hypothesis of the impor- 
tance of proline brackets [1]. 
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